Drs. Rafael Bejar (San Diego) and Moshe Mittelman (Tel Aviv) discuss several papers highlighting the role of genetics in MDS diagnosis, follow up and prediction of treatment. They also discuss the role of the newly approved luspatercept in the treatment of anemic transfusion-dependent patients with lower-risk MDS
Information
- Show
- FrequencyEvery two months
- Published28 September 2022 at 07:23 UTC
- Length22 min
- Season2
- Episode2
- RatingClean